imed biotech unit 2017 – a year in review...year-on-year. 625 publications in total, of which, 44...
TRANSCRIPT
Innovative Medicines and Early Development Biotech Unit2017 – A year in review
Delivering the next wave of scientific innovation
We are now in a better position than ever to enable the translation of innovative science into medicines.
This has been achieved by embedding the 5R framework, since 2010, into everything we do and at the same time establishing an open, collaborative, truth-seeking culture with scientific rigour at its heart.
Delivering the next wave of scientific innovations
IMED Biotech Unit 2017 – A year in review
IMED Biotech Unit 5R Framework
5RWe published our second 5R framework review in Nature Reviews Drug Discovery
5 years>4xIncreased productivity over the last
Pre-clinical assessment to Phase III completion rates were increased to
from 4% since 201219%
Right Tissue
Right Target
Right Commercial
Right Safety
Right Patient
5R framework
IMED Biotech Unit: 2017 Publications
Our increased R&D productivity is mirrored by a substantial rise in the number of peer-reviewed research publications –
625 in total, of which 44 were in high-impact journals
Attracting the brightest minds and best talent:
IMED employs 2400 people including 120 post docs
We made 433 new hires in 2017
Increased the number of women in senior roles from
31 to 42% since 2012 (target of 45–55% by 2020)
IMED Biotech Unit: 2017 in numbers
Driving research and development productivity:
19 diagnostics launched
16 Phase I and II Novel Molecular Entity starts
3 Phase III investment decisions
Collaborating for science innovation:
1165 current collaborations
74 Open Innovation projects
~40 major academic/industrial collaborations
The diversity of our pipeline pushes the boundaries of science, delivering the next wave of innovation beyond small molecules, and strengthening our position as a leader in precision medicine and genomics.
IMED Biotech Unit: 2017 pipeline and innovation
Precision medicine and genomics
a 10% increase from 2016
~90%of our clinical pipeline follows a precision medicine approach
10% of our target of 2 million by 2026
200,000 genomes,
Our Centre for Genomics Research has analysed over
New modalitiesWe are on a quest to transform and, ultimately, cure diseases. To get there, we need to be able to target any novel biology we uncover.
That’s why we are making our drug platforms more diverse, expanding beyond the traditional small molecules, monoclonal antibodies and peptides.
PROTACs Therapeutic proteins
Anticalin® proteins
Antisense oligonucleotides
Oligonucleotide conjugates
Modified mRNA
Bicyclic peptides
~30%of programmes
focus onnew modalities
IMED’s seven drug modalities in addition to small molecules:
IMED Biotech Unit 2017 – A year in review
95 in Asia Pacific
190 in Europe
380 in the UK410
in the US
In total, we have 1165 current collaborations across industry and academia
Our continued success and growth was driven by our agile and entrepreneurial culture, our network of partnerships and the extraordinary people who make up our workforce.
IMED Biotech Unit: 2017 collaborations
90 in Sweden
IMED Biotech Unit: 2017 approaches to Open InnovationIn 2017 we...Our IMED Open
Innovation portal allows external researchers to access all our open innovation programmes.
500proposals for new drug projects
250partnerships
...reviewed more than ...formed more than
...initiated or planned
250 pre-clinical studies and 30clinical
trials
IMED Biotech Unit: 2017 key partnershipsIn 2017, our IMED team established close to 40 major collaborations. Here are some highlights:
New industrial partnership with Bicycle Therapeutics, to develop new drugs based on their proprietary bicyclic peptides
Global strategic collaboration with Merck to co-develop olaparib
New collaboration with Pieris to develop novel inhaled Anticalin® proteins
New five-year initiative with The Crick Institute, focusing on early stage research
Uncovering the structure of ATM, through our blue sky research partnership with MRC-LMB and University of Cambridge, and made possible through the cryo-EM consortium
A new joint research laboratory with Imperial College, focusing on respiratory disease
2017 in numbers:Driving research and development productivity:
19 diagnostics launched
16 Phase I and II Novel Molecular Entity starts
3 Phase III investment decisions
Pre-clinical assessment to Phase III completion rates were increased to
19%from 4% since 2012
>4xIncreased productivity over the last
5 years
We published our second 5R framework review in Nature Reviews Drug Discovery
5RPublications
Collaborating for science innovation: IMED employs 2400 people including 120 post docs
We made 433 new hires in 2017
Increased the number of women in senior roles from 31 to 42% since 2012
1165 current collaborations
74 Open Innovation projects
~40 major academic/industrial collaborations
Right Tissue
Right Target
Right Commercial
Right Safety
Right Patient
5R framework
We continue to outperform our publication achievements year-on-year.
625 publications in total,
of which, 44 were high-impact
IMED Biotech Unit: 2017 in review We are now in a better position than ever to enable the translation of innovative science into medicines. This has been achieved by embedding the 5R framework, since 2010, into everything we do and at the same time establishing an open, collaborative, truth-seeking culture with scientific rigour at its heart.
Precision medicine and genomics
Our goal is to develop innovative, targeted medicines for every patient that needs them, and to match those treatments to patients most likely to benefit from them.
New modalities
Medicines of tomorrow will be different from those of today. We are on a quest to transform and, ultimately, cure diseases.
PROTACs
Therapeutic proteins
Anticalin® proteins
Antisense oligonucleotides
Oligonucleotide conjugates
Modified mRNA
Bicyclic peptides
a 10% increase from 2016
~90%of our clinical pipeline follows a precision medicine approach
10% of our target of 2 million by 2026
200,000 genomes
Our Centre for Genomics Research has analysed over
IMED’s 7 drug modalities in addition to small molecules:
of programmes focus on
new modalities
~30%
2017: Pipeline and innovation The diversity of our pipeline pushes the boundaries of science, delivering the next wave of innovation beyond small molecules, and strengthening our position as a leader in precision medicine and genomics.
Key partnerships in 2017:
In total, we have 1165 current collaborations across industry and academia
410 in the US 380
in the UK
190 in Europe
95 in Asia Pacific
90 in Sweden
Our new IMED Open Innovation portal allows external researchers to access all our open innovation programmes.
New approaches to open innovation
New industrial partnership with Bicycle Therapeutics, to develop new drugs based on their proprietary bicyclic peptides.
Global strategic collaboration with Merck to co-develop olaparib
New five-year initiative with The Crick Institute, focusing on early stage research
New strategic collaboration with Pieris to develop novel inhaled Anticalin®-based treatments
Uncovering the structure of ATM, through our blue sky research partnership with MRC-LMB and University of Cambridge, and made possible through the cryo-EM consortium
A new joint research laboratory with Imperial College, focusing on respiratory disease
2017: Collaborations, culture and people Our continued success and growth was driven by our agile and entrepreneurial culture, our network of partnerships and the extraordinary people who make up our workforce.
...initiated or planned
250 pre-clinical studies
...and
30 clinical trials
...reviewed more than
500proposals for new drug projects
...reviewed more than
250partnerships